# Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease

> **NCT00976352** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Florida** · enrollment: 9 (actual)

## Conditions studied

- Pompe Disease

## Interventions

- **DRUG:** rAAV1-CMV-GAA (study agent) Administration
- **OTHER:** RMST

## Key facts

- **NCT ID:** NCT00976352
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976352, "Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00976352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*